Clyde Bailey

1.9k total citations · 1 hit paper
35 papers, 1.3k citations indexed

About

Clyde Bailey is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Clyde Bailey has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 21 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Clyde Bailey's work include Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (15 papers) and Cancer Treatment and Pharmacology (7 papers). Clyde Bailey is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (15 papers) and Cancer Treatment and Pharmacology (7 papers). Clyde Bailey collaborates with scholars based in United States, Jordan and United Kingdom. Clyde Bailey's co-authors include Denise Sheer, E. Solomon, Walter F. Bodmer, Victoria A. Murday, Anthony Ellis, Patricia Gorman, Sue Rider, H J R Bussey, J. G. Bodmer and Frances C. Lucibello and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Clyde Bailey

31 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Localization of the gene for familial adenomatous polyposis on chromosome 5

1987 1.0k citations Clyde Bailey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clyde Bailey United States	10	702	645	425	302	208	35	1.3k
Teresa Flores Spain	19	414 0.6×	492 0.8×	539 1.3×	177 0.6×	255 1.2×	25	1.3k
Carsten Schwäenen Germany	19	420 0.6×	377 0.6×	663 1.6×	362 1.2×	151 0.7×	25	1.4k
Laura Valle Spain	19	881 1.3×	632 1.0×	576 1.4×	488 1.6×	59 0.3×	61	1.5k
Pascale De Paepe Belgium	15	564 0.8×	387 0.6×	268 0.6×	136 0.5×	140 0.7×	36	999
Dirk Kienle Germany	24	807 1.1×	358 0.6×	630 1.5×	273 0.9×	172 0.8×	37	1.7k
Samuli Hemmer Finland	10	312 0.4×	410 0.6×	694 1.6×	340 1.1×	42 0.2×	12	1.4k
Olga Balagué Spain	22	827 1.2×	686 1.1×	440 1.0×	285 0.9×	52 0.3×	51	1.6k
Nasser Z. Parsa United States	15	764 1.1×	486 0.8×	352 0.8×	158 0.5×	82 0.4×	22	1.2k
S. D. Finkelstein United States	16	445 0.6×	304 0.5×	219 0.5×	326 1.1×	100 0.5×	25	982
Wook Youn Kim South Korea	16	354 0.5×	403 0.6×	233 0.5×	164 0.5×	45 0.2×	49	925

Countries citing papers authored by Clyde Bailey

Since Specialization

Citations

This map shows the geographic impact of Clyde Bailey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clyde Bailey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clyde Bailey more than expected).

Fields of papers citing papers by Clyde Bailey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clyde Bailey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clyde Bailey. The network helps show where Clyde Bailey may publish in the future.

Co-authorship network of co-authors of Clyde Bailey

This figure shows the co-authorship network connecting the top 25 collaborators of Clyde Bailey. A scholar is included among the top collaborators of Clyde Bailey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clyde Bailey. Clyde Bailey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hadidi, Samer Al, Carolina Schinke, Sharmilan Thanendrarajan, et al.. (2025). Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols. JAMA Oncology. 11(8). 910–910.

Cheng, Yan, Fumou Sun, Daisy Alapat, et al.. (2024). Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer Journal. 14(1). 194–194. 13 indexed citations

Cheng, Yan, Fumou Sun, Daisy Alapat, et al.. (2024). Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages. Blood. 144(Supplement 1). 4729–4729.

Hadidi, Samer Al, Carolina Schinke, Sharmilan Thanendrarajan, et al.. (2024). Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood Advances. 9(4). 950–953. 2 indexed citations

Hadidi, Samer Al, Carolina Schinke, Sharmilan Thanendrarajan, et al.. (2023). Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Advances. 8(3). 703–707. 5 indexed citations

Wanchai, Visanu, Cody Ashby, Hongwei Xu, et al.. (2023). Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease. Blood. 142(Supplement 1). 1932–1932. 1 indexed citations

Schinke, Carolina, Leo Rasche, Cody Ashby, et al.. (2023). Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma. Blood. 142(Supplement 1). 882–882. 2 indexed citations

Hadidi, Samer Al, Carolina Schinke, Sharmilan Thanendrarajan, et al.. (2023). Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB.. Journal of Clinical Oncology. 41(16_suppl). e20053–e20053. 1 indexed citations

Larsen, Kristin Kampevold, Meera Mohan, Clyde Bailey, et al.. (2020). Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood. 136(Supplement 1). 44–44. 2 indexed citations

10.

Sawyer, Jeffrey R., Erming Tian, Brian A. Walker, et al.. (2019). An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal. 9(8). 62–62. 30 indexed citations

11.

Sawyer, Jeffery R., Erming Tian, Brian A. Walker, et al.. (2018). An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. Blood. 132(Supplement 1). 4489–4489. 5 indexed citations

12.

Sawyer, Jeffrey R., John D. Shaughnessy, Joshua Epstein, et al.. (2016). Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 31(3). 637–644. 21 indexed citations

13.

Khan, Rashid, Madhav V. Dhodapkar, Adam Rosenthal, et al.. (2015). Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 100(9). 1214–1221. 34 indexed citations

14.

Papanikolaou, Xanthos, Daisy Alapat, Adam Rosenthal, et al.. (2015). The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia. 29(8). 1713–1720. 4 indexed citations

15.

Singh, Zeba N., Yogesh Jethava, Ginell R. Post, et al.. (2015). Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clinical Case Reports. 3(3). 183–192. 1 indexed citations

16.

Papanikolaou, Xanthos, Jackie Szymonifka, Adam Rosenthal, et al.. (2013). Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica. 98(7). 1147–1153. 10 indexed citations

17.

Heuck, Christoph, Jackie Szymonifka, John D. Shaughnessy, et al.. (2012). Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1. Clinical Cancer Research. 18(19). 5499–5506. 13 indexed citations

18.

Anaissie, Elias, Elizabeth Ann Coleman, Julia A. Goodwin, et al.. (2011). Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 118(2). 549–557. 43 indexed citations

19.

Hoering, Antje, Jeffrey R. Sawyer, Frits van Rhee, et al.. (2008). Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia. 22(4). 850–855. 10 indexed citations

20.

Bumm, Klaus, Mingzhong Zheng, Clyde Bailey, et al.. (2002). CGO: utilizing and integrating gene expression microarray data in clinical research and data management. Bioinformatics. 18(2). 327–328. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact